Myovant Sciences Ltd. was thrilled with Tuesday's data announcement from the first of two phase III studies of relugolix, in which Liberty 1 met its primary efficacy endpoint and six secondary endpoints in women with uterine fibroids. The results keep the phase III races tight between relugolix, Abbvie Inc.'s elagolix and Obseva SA's OBE-2109.